Shin Yang Group Berhad Third Quarter 2025 Earnings: EPS: RM0.041 (vs RM0.031 in 3Q 2024)
Net income: RM46.4m (up 34% from 3Q 2024).
Profit margin: 11% (down from 14% in 3Q 2024). The decrease in margin was driven by higher expenses.
EPS: RM0.041 (up from RM0.031 in 3Q 2024).
AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.
All figures shown in the chart above are for the trailing 12 month (TTM) period
Shin Yang Group Berhad shares are up 6.7% from a week ago.
While earnings are important, another area to consider is the balance sheet. See our latest analysis on Shin Yang Group Berhad's balance sheet health.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Erreur lors de la récupération des données
Connectez-vous pour accéder à votre portefeuille
Erreur lors de la récupération des données
Erreur lors de la récupération des données
Erreur lors de la récupération des données
Erreur lors de la récupération des données
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
29 minutes ago
- Yahoo
What Canadian National Railway (TSX:CNR)'s Reduced Earnings Guidance Means For Shareholders
Earlier this month, Canadian National Railway faced ongoing operational challenges and reported that its expected business turnaround had not materialized, leading to reduced earnings growth guidance. This setback has sparked negative sentiment, with some industry observers drawing comparisons to competitors viewed as better positioned for growth and highlighting alternatives within the sector. With reduced earnings growth guidance in focus, we'll explore how these operational issues may shift Canadian National Railway's investment narrative. AI is about to change healthcare. These 27 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early. Canadian National Railway Investment Narrative Recap To be a shareholder in Canadian National Railway, you need confidence in the company's ability to capitalize on long-term shifts toward intermodal and bulk transport as industries focus on supply chain resilience and North American trade. However, the recent reduction in earnings growth guidance directly impacts the key short-term catalyst, an expected business turnaround, and highlights concerns around volume growth, currently the most prominent risk for the business. The news meaningfully shifts investor attention from network advantages to near-term operational execution. Among recent announcements, the second-quarter results stand out. While CN grew net income and earnings per share compared to the prior year, sales have edged lower, reflecting the ongoing volume and demand pressures underpinning the news event. This reinforces the theme that even targeted capital spending and cost discipline will take time to translate into renewed growth, particularly if market conditions stay challenging. In contrast, investors should also be aware that structural shifts in customer routing and industry competitiveness could... Read the full narrative on Canadian National Railway (it's free!) Canadian National Railway's narrative projects CA$19.6 billion revenue and CA$5.6 billion earnings by 2028. This requires 4.6% yearly revenue growth and a CA$1.0 billion earnings increase from CA$4.6 billion today. Uncover how Canadian National Railway's forecasts yield a CA$153.14 fair value, a 19% upside to its current price. Exploring Other Perspectives Simply Wall St Community members provided 12 fair value estimates for CNR ranging from CA$119.59 to CA$170.64 per share. These divergent opinions come as growth in shipping volumes remains a critical uncertainty for the company's ability to regain momentum, explore the range of forecasts and viewpoints from across the Community. Explore 12 other fair value estimates on Canadian National Railway - why the stock might be worth 7% less than the current price! Build Your Own Canadian National Railway Narrative Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd. A great starting point for your Canadian National Railway research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision. Our free Canadian National Railway research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Canadian National Railway's overall financial health at a glance. Want Some Alternatives? Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay: Outshine the giants: these 19 early-stage AI stocks could fund your retirement. The latest GPUs need a type of rare earth metal called Dysprosium and there are only 28 companies in the world exploring or producing it. Find the list for free. Trump's oil boom is here - pipelines are primed to profit. Discover the 22 US stocks riding the wave. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Arvinas, Pfizer's Vepdegestrant NDA Accepted by FDA for Breast Cancer Treatment
Arvinas Inc. (NASDAQ:ARVN) is one of the best small cap stocks with biggest upside potential. On August 8, Arvinas, in collaboration with Pfizer Inc. (NYSE:PFE), announced that the US FDA accepted its New Drug Application/NDA for vepdegestrant. The drug is intended to treat patients with estrogen receptor-positive/ER+, human epidermal growth factor receptor 2-negative/HER2-, ESR1-mutated advanced or metastatic breast cancer who have already received endocrine-based therapy. The FDA has set a Prescription Drug User Fee Act/PDUFA action date of June 5, 2026. The NDA is based on data from the Phase 3 VERITAC-2 clinical trial, which showed a statistically significant and clinically meaningful improvement in median progression-free survival for vepdegestrant compared to fulvestrant. The trial enrolled 624 patients at 213 sites across 25 countries, with 270 of these patients having the ESR1 mutation. A biopharma executive in a meeting room discussing the clinical-stage of a new therapy. The results from this trial were recently presented at the American Society of Clinical Oncology/ASCO 2025 Annual Meeting and published in The New England Journal of Medicine. Vepdegestrant is an investigational oral drug that functions as a PROteolysis TArgeting Chimera/PROTAC estrogen receptor degrader. This marks the first time a PROTAC has demonstrated a clinical benefit in breast cancer patients. Arvinas Inc. (NASDAQ:ARVN) is a clinical-stage biotechnology company that engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Pfizer Inc. (NYSE:PFE) discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the US and internationally. While we acknowledge the potential of ARVN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
2 hours ago
- Yahoo
TAG Immobilien (ETR:TEG) Strong Profits May Be Masking Some Underlying Issues
Explore TAG Immobilien's Fair Values from the Community and select yours The recent earnings posted by TAG Immobilien AG (ETR:TEG) were solid, but the stock didn't move as much as we expected. However the statutory profit number doesn't tell the whole story, and we have found some factors which might be of concern to shareholders. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. How Do Unusual Items Influence Profit? To properly understand TAG Immobilien's profit results, we need to consider the €136m gain attributed to unusual items. While we like to see profit increases, we tend to be a little more cautious when unusual items have made a big contribution. When we crunched the numbers on thousands of publicly listed companies, we found that a boost from unusual items in a given year is often not repeated the next year. Which is hardly surprising, given the name. TAG Immobilien had a rather significant contribution from unusual items relative to its profit to June 2025. As a result, we can surmise that the unusual items are making its statutory profit significantly stronger than it would otherwise be. That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates. Our Take On TAG Immobilien's Profit Performance As previously mentioned, TAG Immobilien's large boost from unusual items won't be there indefinitely, so its statutory earnings are probably a poor guide to its underlying profitability. As a result, we think it may well be the case that TAG Immobilien's underlying earnings power is lower than its statutory profit. The good news is that it earned a profit in the last twelve months, despite its previous loss. The goal of this article has been to assess how well we can rely on the statutory earnings to reflect the company's potential, but there is plenty more to consider. If you want to do dive deeper into TAG Immobilien, you'd also look into what risks it is currently facing. When we did our research, we found 3 warning signs for TAG Immobilien (1 is potentially serious!) that we believe deserve your full attention. This note has only looked at a single factor that sheds light on the nature of TAG Immobilien's profit. But there are plenty of other ways to inform your opinion of a company. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks with high insider ownership. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
